Psoriatic Arthritis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Amgen, Novartis, Pfizer, Ventyx Biosciences, UCB Biopharma, Sun Pharma

 Breaking News
  • No posts were found

Psoriatic Arthritis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Amgen, Novartis, Pfizer, Ventyx Biosciences, UCB Biopharma, Sun Pharma

June 06
09:37 2023
Psoriatic Arthritis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Amgen, Novartis, Pfizer, Ventyx Biosciences,  UCB Biopharma, Sun Pharma
DelveInsight’s “Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Psoriatic Arthritis.

DelveInsight’s “Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Psoriatic Arthritis, historical and forecasted epidemiology as well as the Psoriatic Arthritis market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Psoriatic Arthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Psoriatic Arthritis Market Forecast

 

Some of the key facts of the Psoriatic Arthritis Market Report: 

  • The Psoriatic Arthritis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • As many as 2.4 million Americans, or 30% of those with psoriasis, go on to develop psoriatic arthritis (PsA), which can strike at any age, according to the National Psoriatic Foundation
  • According to a study by Pérez et al. [2020], Spain had one of the highest reported rates of PsA to date, just slightly lower than Norway (0.67%) and slightly higher than Italy (0.42%)
  • Key Psoriatic Arthritis Companies: Sun Pharma, Bristol-Myers Squibb, Nimbus Therapeutics, UCB Biopharma, Pfizer, Astellas Pharma Inc., Biogen, ACELYRIN Inc., Sun Pharmaceutical, Amgen, Novartis, Ventyx Biosciences, Janssen Research & Development, Aclaris Therapeutics, and others
  • Key Psoriatic Arthritis Therapies: Ilumya, Deucravacitinib, NDI-034858, Bimekizumab, Brepocitinib, Alefacept, Methotrexate, Izokibep, SUNPG18_07, Etanercept, Secukinumab, Tofacitinib, VTX958, Guselkumab, ATI-450, and others
  • The Psoriatic Arthritis epidemiology based on gender analyzed that there is no gender based difference but prevalence of severe cases is the highest followed by moderate and mild
  • The Psoriatic Arthritis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Psoriatic Arthritis pipeline products will significantly revolutionize the Psoriatic Arthritis market dynamics.

 

Psoriatic Arthritis Overview

Psoriatic arthritis (PsA) is a diverse type of chronic inflammatory rheumatic illness that causes joint erosion, bone growth, stiffness, pain, and swelling. Clinical signs differ widely from patient to patient. It can manifest as a polyarticular illness affecting five or more joints, frequently with an asymmetric distribution comparable to that of rheumatoid arthritis, or as oligoarticular joint involvement that is typically asymmetric.

 

Get a Free sample for the Psoriatic Arthritis Market Report 

https://www.delveinsight.com/report-store/psoriatic-arthritis-market

 

Psoriatic Arthritis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Psoriatic Arthritis Epidemiology Segmentation:

The Psoriatic Arthritis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Psoriatic Arthritis
  • Prevalent Cases of Psoriatic Arthritis by severity
  • Gender-specific Prevalence of Psoriatic Arthritis
  • Diagnosed Cases of Episodic and Chronic Psoriatic Arthritis

 

Download the report to understand which factors are driving Psoriatic Arthritis epidemiology trends @ Psoriatic Arthritis Epidemiology Forecast

 

Psoriatic Arthritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Psoriatic Arthritis market or expected to get launched during the study period. The analysis covers Psoriatic Arthritis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Psoriatic Arthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Psoriatic Arthritis Therapies and Key Companies

  • Ilumya: Sun Pharma
  • Deucravacitinib: Bristol-Myers Squibb
  • NDI-034858: Nimbus Therapeutics
  • Bimekizumab: UCB Biopharma
  • Brepocitinib: Pfizer
  • Alefacept: Astellas Pharma Inc
  • Methotrexate: Biogen
  • Izokibep: ACELYRIN Inc.
  • SUNPG18_07: Sun Pharmaceutical
  • Etanercept: Amgen
  • Secukinumab: Novartis
  • Tofacitinib: Pfizer
  • VTX958: Ventyx Biosciences
  • Guselkumab: Janssen Research & Development
  • ATI-450: Aclaris Therapeutics

 

Discover more about therapies set to grab major Psoriatic Arthritis market share @ Psoriatic Arthritis Treatment Market

 

Psoriatic Arthritis Market Strengths

  • Widespread prevalence of the disease
  • The robust clinical pipeline containing emerging drugs with novel RoA and MoA holds promising future therapies

 

Psoriatic Arthritis Market Opportunities

  • Challenges in diagnoses
  • Development of novel therapies
  • Limitations in gene therapy
  • Poor disease understanding
  • Clinical biomarkers

 

Scope of the Psoriatic Arthritis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Psoriatic Arthritis Companies: Sun Pharma, Bristol-Myers Squibb, Nimbus Therapeutics, UCB Biopharma, Pfizer, Astellas Pharma Inc., Biogen, ACELYRIN Inc., Sun Pharmaceutical, Amgen, Novartis, Pfizer, Ventyx Biosciences, Janssen Research & Development, Aclaris Therapeutics, and others
  • Key Psoriatic Arthritis Therapies: Ilumya, Deucravacitinib, NDI-034858, Bimekizumab, Brepocitinib, Alefacept, Methotrexate, Izokibep, SUNPG18_07, Etanercept, Secukinumab, Tofacitinib, VTX958, Guselkumab, ATI-450, and others
  • Psoriatic Arthritis Therapeutic Assessment: Psoriatic Arthritis current marketed and Psoriatic Arthritis emerging therapies
  • Psoriatic Arthritis Market Dynamics: Psoriatic Arthritis market drivers and Psoriatic Arthritis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Psoriatic Arthritis Unmet Needs, KOL’s views, Analyst’s views, Psoriatic Arthritis Market Access and Reimbursement 

 

To know more about Psoriatic Arthritis companies working in the treatment market, visit @ Psoriatic Arthritis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Psoriatic Arthritis Market Report Introduction

2. Executive Summary for Psoriatic Arthritis

3. SWOT analysis of Psoriatic Arthritis

4. Psoriatic Arthritis Patient Share (%) Overview at a Glance

5. Psoriatic Arthritis Market Overview at a Glance

6. Psoriatic Arthritis Disease Background and Overview

7. Psoriatic Arthritis Epidemiology and Patient Population

8. Country-Specific Patient Population of Psoriatic Arthritis 

9. Psoriatic Arthritis Current Treatment and Medical Practices

10. Psoriatic Arthritis Unmet Needs

11. Psoriatic Arthritis Emerging Therapies

12. Psoriatic Arthritis Market Outlook

13. Country-Wise Psoriatic Arthritis Market Analysis (2019–2032)

14. Psoriatic Arthritis Market Access and Reimbursement of Therapies

15. Psoriatic Arthritis Market Drivers

16. Psoriatic Arthritis Market Barriers

17.  Psoriatic Arthritis Appendix

18. Psoriatic Arthritis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Related Articles

Categories